GlassScriptPhysician profile
Deborah Hansard
NPI 1437180957
$3,346.99
in general payments reported to CMS, 2019-2025
13 companies · $529 in 2025
The $529 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $28.48 · 2021: $661 · 2022: $819 · 2023: $402 · 2024: $757 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $730.99 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $563.50 | 2019-2025 | Ingrezza |
| Abbvie INC. | $523.84 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $356.22 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $354.99 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.51 | 2021-2025 | Caplyta |
| Alkermes, INC. | $245.94 | 2019-2023 | Aristada, Lybalvi |
| Indivior INC. | $132.24 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $58.01 | 2024-2025 | Cobenfy |
| Allergan, INC. | $31.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $24.85 | 2021 | |
| Lundbeck LLC | $18.28 | 2019 | |
| Noven Therapeutics, LLC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hansard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.